Drug intelligence / Profile preview

painjiabin

Development stage: Unknown
Lead developer: Suzhou Wangshan Wangshui Biopharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Painjiabin (TPN102) is a novel small molecule antiepileptic drug developed by the Shanghai Institute of Materia Medica (SIMM). It acts as a potent and selective opener of KCNQ2/3 (Kv7.2/7.3) potassium channels. By enhancing the M-current, it stabilizes the resting membrane potential and controls neuronal excitability, which is a validated mechanism for treating focal epilepsy. It is currently being evaluated in Phase II clinical trials in China as an add-on therapy for adult patients with drug-resistant focal epilepsy who are inadequately controlled or intolerant to other antiepileptic drugs.

Other names: 派安加滨Painjiabin

Targets

GABRR (GABA-A receptor subunit rho)

Beyond the preview

Go deeper on painjiabin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on painjiabin.

Explore the full profile